Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Whitehawk Therapeutics (WHWK) EBITDA Margin (2018 - 2025)

Historic EBITDA Margin for Whitehawk Therapeutics (WHWK) over the last 7 years, with Q1 2025 value amounting to 1021.71%.

  • Whitehawk Therapeutics' EBITDA Margin rose 13640200.0% to 1021.71% in Q1 2025 from the same period last year, while for Sep 2025 it was 107.88%, marking a year-over-year increase of 1379600.0%. This contributed to the annual value of 245.17% for FY2024, which is 242900.0% up from last year.
  • Whitehawk Therapeutics' EBITDA Margin amounted to 1021.71% in Q1 2025, which was up 13640200.0% from 252.74% recorded in Q4 2024.
  • In the past 5 years, Whitehawk Therapeutics' EBITDA Margin registered a high of 1021.71% during Q1 2025, and its lowest value of 3405.83% during Q1 2021.
  • Its 5-year average for EBITDA Margin is 421.8%, with a median of 266.48% in 2022.
  • The largest annual percentage gain for Whitehawk Therapeutics' EBITDA Margin in the last 5 years was 28051800bps (2022), contrasted with its biggest fall of -1476500bps (2022).
  • Whitehawk Therapeutics' EBITDA Margin (Quarter) stood at 118.84% in 2021, then crashed by -124bps to 266.48% in 2022, then rose by 4bps to 256.5% in 2023, then rose by 1bps to 252.74% in 2024, then skyrocketed by 504bps to 1021.71% in 2025.
  • Its EBITDA Margin was 1021.71% in Q1 2025, compared to 252.74% in Q4 2024 and 173.04% in Q3 2024.